Australian clinical-stage company Immutep has announced positive data from the INSIGHT-003 trial evaluating its eftilagimod alpha in combination with MSD's KEYTRUDA (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer. …
Australian company says 'Efti' INSIGHT-003 lung cancer trial reveals positive survival data
November 14, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
BPDInsights one week out with patient voices leading the agenda
May 11, 2026 - - Latest News -
It's mostly a mistake to read too much into a Budget forecast because of what it doesn't include
May 11, 2026 - - Latest News -
Budget silence on HTA Review would confirm what we already know - delayed rollout
May 9, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 8 May 2026
May 8, 2026 - - Podcast -
Lilly marks 150 years by lighting a new horizon for health at Vivid Sydney
May 8, 2026 - - Latest News -
The approaching major change in Australia’s PBS wholesaling arrangements
May 8, 2026 - - Latest News -
Victoria joins state-funded MenB programs as PBAC rejection creates another 'postcode lottery'
May 8, 2026 - - Latest News